BYETTA PACKAGE INSERT PDF

BYETTA is a non-insulin type 2 diabetes injection medication for adults. Learn about BYETTA, the BYETTA Pen. in patients with prior severe hypersensitivity reactions to exenatide or to any of the product components. Patient Information Leaflet. Package leaflet: Information for the patient. Byetta 5 micrograms solution for injection in pre-filled pen. Byetta 10 micrograms solution .

Author: Kegami Dijinn
Country: Malta
Language: English (Spanish)
Genre: Marketing
Published (Last): 4 August 2017
Pages: 290
PDF File Size: 14.25 Mb
ePub File Size: 3.19 Mb
ISBN: 690-9-91169-989-9
Downloads: 78895
Price: Free* [*Free Regsitration Required]
Uploader: Mikagal

To report drug exposure during pregnancy call Signs and symptoms of low blood sugar may include headache, drowsiness, weakness, dizziness, confusion, irritability, hunger, fast heartbeat, sweating, and feeling jittery. Glucagon-like peptide-1 receptor agonist or bolus insulin with optimized basal insulin in type 2 diabetes. Pen-sharing poses a risk for transmission of blood-borne pathogens, even if the needle is changed. The site you are about to visit is maintained by a third party who is solely responsible for its contents.

Increased risk of hypoglycemia when used in combination with a sulfonylurea SU or when used with a glucose-independent insulin secretagogues eg, meglitinides. Postmarketing reports of altered renal function, including increased serum creatinine, renal impairment, worsened chronic renal failure, and acute renal failure, sometimes requiring hemodialysis and kidney transplantation.

Postmarketing reports of increased international normalized ratio INR sometimes associated with bleeding with concomitant use of warfarin. You may report side effects related to AstraZeneca products by clicking here. Go to Healthcare Professional Site. All other trademarks are property of their respective owners. This site is intended for US Consumers.

Type 2 Diabetes Medication | BYETTA® (exenatide) injection

BYETTA slows gastric emptying and can reduce the extent and rate of absorption of orally administered drugs. You are encouraged to report negative side effects of prescription drugs to the FDA. These may be symptoms of pancreatitis. After initiation and dose increases of BYETTA, observe patients carefully for inserg including persistent severe abdominal pain, sometimes radiating to the back, with or without vomiting.

Talk to your healthcare provider first byetts you are breastfeeding or plan to breastfeed.

Add BYETTA to insulin glargine as a complementary action to help improve glycemic control

Should not be used in patients with severe renal impairment btetta end-stage renal disease. Tell your healthcare provider if you have severe problems with your stomach, such as delayed emptying of your stomach gastroparesis or problems with digesting food. Call your healthcare provider right away if you have nausea, vomiting, or diarrhea that will not go away, or if you cannot take liquids by mouth.

BYETTA has been associated with acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing byetta, based on postmarketing data.

When used with insulin, evaluate and consider reducing the insulin dose in patients at increased risk of hypoglycemia. All other trademarks are property of their respective owners.

Because exenatide is commonly associated with gastrointestinal adverse reactions, BYETTA is not recommended in patients with severe gastrointestinal disease eg gastroparesis. Go to Patient Site. Postmarketing reports of serious hypersensitivity reactions eg anaphylaxis and angioedema. We encourage you to read the privacy policy of every website you visit. Before taking BYETTA, tell your healthcare provider paxkage you have had pancreatitis, stones in your gallbladder gallstonesa history of alcoholism, or high blood triglyceride levels.

Symptoms of a severe allergic reaction pac,age severe rash or itching, swelling of your face, packags, and throat that may cause difficulty breathing or swallowing, feeling faint or dizzy and very rapid heartbeat. AstraZeneca provides this link as a service to website visitors. Use in pediatric patients is not recommended as safety and effectiveness have not been established.

indert No placebo-treated patients withdrew due to nausea or vomiting. No clinical studies establishing conclusive evidence of macrovascular risk reduction with BYETTA or any other antidiabetic drug. It is unknown whether patients with a history of pancreatitis are at increased risk for pancreatitis while using BYETTA; consider other antidiabetic therapies for these patients.

Welcome to BYETTA.com!

The Double B logo is a trademark of the AstraZeneca group of companies. Drug Interactions Oral Medications: Inflammation of the pancreas pancreatitis may happen, which may packae severe and lead to death. BYETTA is an injectable prescription medicine that may improve blood sugar glucose control in adults with type 2 diabetes, when used with diet and exercise. Use with caution in patients with renal transplantation or when initiating or escalating the dose in patients with moderate renal failure.

Oral medications dependent on threshold concentrations for efficacy, such as packagw or antibiotics, should be taken at least 1 hour before BYETTA. If worsening of or failure to achieve adequate glycemic control occurs, consider alternative antidiabetic therapy.

Write your html here The most common side effects with BYETTA include nausea, vomiting, diarrhea, feeling jittery, dizziness, headache, acid stomach, constipation, and weakness. BYETTA is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type insegt diabetes mellitus.

Tell your healthcare provider if you are pregnant or plan to become pregnant. Use of twice-daily exenatide in basal insrt patients with type 2 diabetes: Approved Uses BYETTA is an injectable prescription medicine that may improve blood sugar glucose control in adults with type 2 diabetes, when used with diet and exercise.

Not a substitute for pacoage and should not be used in patients with type 1 diabetes or diabetic ketoacidosis. Concurrent use with prandial insulin has not been studied and cannot be recommended. Stop taking BYETTA and call your healthcare provider right away if you have pain in your stomach area abdomen that is severe, and will not go away, occurs with or without vomiting or is felt going from your abdomen through to byyetta back.

Your risk for getting low blood sugar hypoglycemia is higher if iinsert take BYETTA with another medicine that can cause low blood sugar, such as a sulfonylurea or insulin. AstraZeneca is not responsible for the privacy policy of any third-party websites.

BYETTA should not be used in people with type 1 diabetes or people with diabetic ketoacidosis a condition caused by very high blood sugar.

Official BYETTA® (exenatide) injection Healthcare Professional Website

Based on animal data, BYETTA may cause fetal harm and should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Tell your healthcare provider if you have or had kidney problems or a kidney transplant.

Based on postmarketing data BYETTA has been associated with acute pancreatitis, including bydtta and non-fatal hemorrhagic or necrotizing pancreatitis.

Author: admin